Bacil Pharma Limited (BOM:524516)

Bacil Pharma Statistics

Total Valuation

Bacil Pharma has a market cap or net worth of INR 660.96 million. The enterprise value is 645.02 million.

Market Cap	660.96M
Enterprise Value	645.02M

Important Dates

The next estimated earnings date is Monday, May 25, 2026.

Earnings Date	May 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Bacil Pharma has 14.35 million shares outstanding. The number of shares has increased by 116.22% in one year.

Current Share Class	14.35M
Shares Outstanding	14.35M
Shares Change (YoY)	+116.22%
Shares Change (QoQ)	-5.31%
Owned by Insiders (%)	70.55%
Owned by Institutions (%)	n/a
Float	4.15M

Valuation Ratios

The trailing PE ratio is 76.86.

PE Ratio	76.86
Forward PE	n/a
PS Ratio	n/a
PB Ratio	2.51
P/TBV Ratio	2.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	87.44
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	n/a
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-365.81

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	-0.74%
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	7.15%
Revenue Per Employee	n/a
Profits Per Employee	3.69M
Employee Count	2
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, Bacil Pharma has paid 2.30 million in taxes.

Income Tax	2.30M
Effective Tax Rate	23.73%

Stock Price Statistics

The stock price has increased by +21.08% in the last 52 weeks. The beta is 0.53, so Bacil Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.53
52-Week Price Change	+21.08%
50-Day Moving Average	44.80
200-Day Moving Average	40.76
Relative Strength Index (RSI)	46.71
Average Volume (20 Days)	20,433

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-2.41M
Pretax Income	9.67M
Net Income	7.38M
EBITDA	-2.42M
EBIT	-2.41M
Earnings Per Share (EPS)	0.60

Balance Sheet

The company has 15.94 million in cash and n/a in debt, with a net cash position of 15.94 million or 1.11 per share.

Cash & Cash Equivalents	15.94M
Total Debt	n/a
Net Cash	15.94M
Net Cash Per Share	1.11
Equity (Book Value)	263.50M
Book Value Per Share	19.09
Working Capital	n/a

Cash Flow

Operating Cash Flow	n/a
Capital Expenditures	n/a
Depreciation & Amortization	-2,750
Net Borrowing	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Bacil Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-116.22%
Shareholder Yield	-116.22%
Earnings Yield	1.12%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1